Susquehanna International Group, LLP Aridis Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 16, 2023	BUY	$0.31 - $1.5 $7,155 - $34,623	23,082 New	23,082 $7,000
Q2 2022 Aug 15, 2022	SELL	$0.91 - $1.7 $9,512 - $17,770	-10,453 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.33 - $2.59 $58,808 - $114,522	-44,217 Reduced 80.88%	10,453 $18,000
Q4 2021 Feb 14, 2022	BUY	$2.0 - $3.65 $109,340 - $199,545	54,670 New	54,670 $127,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.